title: Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group.
abstract: We examined 395 patients with disseminated intravascular coagulation (DIC) divided into two groups: non-leukemic and leukemic. In 58% of the patients as a whole, treatment of DIC resulted in complete or partial remission, while exacerbation and death occurred in 31%. The efficacy of DIC treatment in the non-leukemic group was less than that in the leukemic group, indicating that the outcome of DIC depended, in part, on the underlying disease. We examined hemostatic indicators in relation to DIC score: prothrombin time (PT) ratio, FDP, platelet count, and fibrinogen levels were found to be important indicators for the diagnosis of DIC, but not for Pre-DIC. Plasma levels of fibrin-D-dimer, thrombin-antithrombin complex (TAT), and plasmin-plasmin inhibitor complex (PPIC) were significantly increased in pre-DIC. The efficacy of treatment in relation to the DIC score when the treatment was begun showed that greater efficacy was achieved in pre-DIC than in DIC patients. The outcome was poorer with increasing DIC score, suggesting that early diagnosis and early treatment are important. On examining the relationship between outcome and hemostatic indicators, we found that the PT ratio and the levels of antithrombin, plasminogen, PPIC, the PPIC/TAT ratio, and thrombomodulin were related to outcome, suggesting that very high consumption of blood coagulation factors, liver dysfunction, hypofibrinolysis, or organ failure caused a poor outcome. Although the outcome in DIC patients may not depend substantially on plasma levels of TAT and fibrin-D-dimer, we can use these indicators to treat DIC patients at an early stage.
authors.affiliation: 2nd Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: Y
authors.initials: Y
authors.lastname: Wakita
authors.forename: T
authors.initials: T
authors.lastname: Nakase
authors.forename: M
authors.initials: M
authors.lastname: Shimura
authors.forename: K
authors.initials: K
authors.lastname: Hiyoyama
authors.forename: S
authors.initials: S
authors.lastname: Nagaya
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: H
authors.initials: H
authors.lastname: Shiku
mesh_terms: D000933:Antifibrinolytic Agents / Q000737:chemistry; D000990:Antithrombin III / Q000378:metabolism; D001780:Blood Coagulation Tests; D004211:Disseminated Intravascular Coagulation / Q000150:complications / Q000188:drug therapy*; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005341:Fibrinolysin / Q000737:chemistry; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D007938:Leukemia / Q000150:complications*; D010447:Peptide Hydrolases / Q000378:metabolism; D010976:Platelet Count; D011237:Predictive Value of Tests; D011517:Prothrombin Time; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin